Search results for PX-TA1230

Intetumumab Biosimilar – Anti-ITGAV_ITGB3 mAb – Research Grade, ProteoGenix, PX-TA1230

Description of Intetumumab Biosimilar - Anti-ITGAV_ITGB3 mAb - Research Grade Introduction: Intetumumab Biosimilar is a monoclonal antibody (mAb) that targets the integrin alpha V beta 3 (ITGAV_ITGB3) receptor. It is a research grade antibody that has shown promising results in pre-clinical studies and is being developed as a potential therapeutic agent for various diseases. Structure of Intetumumab Biosimilar: Intetumumab Biosimilar is a humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for its specificity towards the ITGAV_ITGB3 receptor. Activity of Intetumumab Biosimilar: The main activity of Intetumumab Biosimilar is to bind to the ITGAV_ITGB3 receptor, which is a cell surface receptor that plays a crucial role in cell adhesion, migration, and proliferation. This receptor is overexpressed in various types of cancer cells, making it an attractive therapeutic target. By binding to the ITGAV_ITGB3 receptor, Intetumumab Biosimilar blocks its activity and inhibits the growth and spread of cancer cells. Application of Intetumumab Biosimilar: 1. Cancer treatment: Intetumumab Biosimilar has shown promising results in pre-clinical studies as a potential treatment for various types of cancer. It has been shown to inhibit the growth and spread of cancer cells by targeting the ITGAV_ITGB3 receptor. This makes it a potential therapeutic option for cancers such as melanoma, breast cancer, and prostate cancer. 2. Angiogenesis inhibition: Intetumumab Biosimilar has also been studied for its ability to inhibit angiogenesis, which is the formation of new blood vessels. Angiogenesis plays a crucial role in the growth and spread of cancer, and by targeting the ITGAV_ITGB3 receptor, Intetumumab Biosimilar can potentially inhibit this process. 3. Rheumatoid arthritis: The ITGAV_ITGB3 receptor has been implicated in the development of rheumatoid arthritis, a chronic inflammatory disease that affects the joints. By targeting this receptor, Intetumumab Biosimilar has shown potential in reducing inflammation and joint damage in pre-clinical studies. 4. Osteoporosis: Intetumumab Biosimilar has also been studied for its potential in treating osteoporosis, a condition characterized by weak and brittle bones. The ITGAV_ITGB3 receptor has been found to play a role in bone remodeling, and by targeting it, Intetumumab Biosimilar can potentially improve bone density and strength. 5. Other diseases: Apart from the above-mentioned applications, Intetumumab Biosimilar is also being studied for its potential in other diseases such as psoriasis, atherosclerosis, and diabetic retinopathy. The ITGAV_ITGB3 receptor has been found to play a role in the pathogenesis of these diseases, and by targeting it, Intetumumab Biosimilar can potentially provide therapeutic benefits. Conclusion: Intetumumab Biosimilar is a promising research grade antibody that targets the ITGAV_ITGB3 receptor. Its ability to inhibit the growth and spread of cancer cells and its potential in treating other diseases make it a valuable therapeutic option. Further clinical studies are needed to fully understand the potential of Intetumumab Biosimilar and its role in the treatment of various diseases.